Table 1

Clinical course

Demographics and ICU coursePatient APatient B
Age (years)50–5550–55
Body mass index (kg/m²)29.425.7
Rituximab
 IndicationRheumatoid arthritisMantle cell lymphoma
 Last infusion (months prior to COVID-19 infection)41
 Dose (mg)1000828.75
 B cell depletionCompleteComplete
 Gammaglobulin, baseline (mg/dL)140447
Further comorbiditiesHypertensionNone
Tertiary care ICU admission
 Preceding length of COVID-19 symptoms (days)3334
 Preceding hospital stay (days)315
 SARS-CoV-2 confirmation by RT-PCRYesYes
 Mechanical ventilationYesYes
 PaO2/FiO2 (mm Hg)72178
 SOFA score915
 APACHE II score3139
 Leucocytes (×1000/µL)5.63.9
 Lymphocytes (×1000/µL)0.20.7
 Thrombocytes (×1000/µL)9516
 Erythrocytes (×1000/µL)2.72.7
 IL-6 (pg/mL)641518
 Ferritin (µg/L)675723 986
Tertiary care ICU course
 ICU stay (days)925
 Mechanical ventilation (days)610
 Renal replacement therapyNoneIntermittent
 SARS-CoV-2 RNA, airway materialCont. positiveCont. positive
 SARS-CoV-2 RNA, serumCont. positiveCont. negative
 Anti-SARS-CoV-2-Spike-RBD antibodiesNot detectableNot detectable
 ComplicationsHaemorrhageUrinary tract infection
PE
SAB
VT
 Survival on ICU dischargeYesYes
  • APACHE, acute physiology and chronic health evaluation; cont., continuously; ICU, intensive care unit; IL-6, interleukin 6; PE, pulmonary embolism; RBD, receptor binding domaine; RT-PCR, reverse transcription PCR; SAB, subarachnoid haemorrhage; SOFA, sequential organ failure assessment; VT, ventricular tachycardia.